This study is to explore the efficacy and safety of ChiCGB conditioning therapy in patients with high-risk Hodgkin and non-Hodgkin lymphoma.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
30
30 mg oral twice weekly for 2 weeks
6 mg/m2 intravenously once daily for 5 days
2500 mg/m2 intravenously twice weekly for 1 week
2-year progression free survival
Time frame: 2 years from recruitment
2-year overall survival
Time frame: 2 years from recruitment
Treatment related mortality
Time frame: 2 years from recruitment
non-hematologic adverse events
Time frame: 2 years from recruitment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
3.2 mg/kg intravenously once daily for 4 days
autologous hematopoietic stem cells infusion after ChiCGB chemotherapy